Therefore, new therapeutic strategies, such as ARID1A mutations, in OCCC might improve chemotherapy sensitivity, prolong survival, and even prevent malignancy from progressing from endometriosis to OCCC. This evidence concerns the gene ARID1A and endometriosis.